Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Estrella Immunopharma, Inc. (ESLA) had Return on Tangible Equity of 48.81% for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
$-4.80M |
|
-- |
|
-- |
|
$4.80M |
|
$-4.80M |
|
-- |
|
$-4.80M |
|
$-4.80M |
|
$-4.80M |
|
$-4.80M |
|
$-4.80M |
|
$-4.80M |
|
$-4.80M |
|
$-4.80M |
|
37.10M |
|
37.10M |
|
$-0.13 |
|
$-0.13 |
|
| Balance Sheet Financials | |
$2.02M |
|
-- |
|
$1.50M |
|
$3.52M |
|
$13.36M |
|
-- |
|
-- |
|
$13.36M |
|
$-9.84M |
|
$-9.84M |
|
$-9.84M |
|
37.77M |
|
| Cash Flow Statement Financials | |
$-1.61M |
|
-- |
|
$2.32M |
|
$0.92M |
|
$1.63M |
|
$0.71M |
|
$0.47M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.15 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-1.61M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
48.81% |
|
|
Return on Tangible Equity |
48.81% |
-136.26% |
|
48.81% |
|
$-0.26 |
|
$-0.04 |
|
$-0.04 |
|